We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Point-of-Care Hemoglobin Testing Compared with Laboratory Analyzer

By LabMedica International staff writers
Posted on 28 Jan 2014
Hemoglobin concentration is assessed to detect anemia and its associated morbidities and is usually determined from venous or capillary blood samples run on a laboratory analyzer.

The blood sample method requires a needle stick and results can be delayed, and exposes caregivers to risks associated with needle sticks and blood exposure. More...
Noninvasive hemoglobin determination would be of benefit to patients and caregivers because it would allow for quick and painless point-of-care assessment.

Clinical scientists at Long Beach Veterans Administration Healthcare System (CA, USA) enrolled 474 subjects in a study to compare a noninvasive hemoglobin concentration measurement method with the traditional technique. A noninvasive hemoglobin (SpHb) test device was placed on the subject's nondominant ring finger. The sensor was covered with an opaque shield to prevent optical interference. A noninvasive hemoglobin measurement was obtained from each subject. Perfusion index, finger temperature, and oxygen saturation (SpO2), measured by the noninvasive hemoglobin test device, were also recorded.

Immediately following the noninvasive testing, a venous blood sample was obtained and analyzed for reference hemoglobin value (Hb) with a laboratory hematology analyzer (LH 500, Beckman Coulter; Brea, CA, USA). A capillary blood sample was also obtained by finger stick within 15 minutes of the noninvasive reading and the venous sample and analyzed immediately with a HemoCue 201 point-of-care hemoglobinometer (Cypress, CA, USA). The noninvasive hemoglobin (SpHb) test device was the Pronto-7, version 2.19, with a rainbow 4D sensor, rev E, (Masimo Corp., Irvine, CA, USA).

The reference hemoglobin concentration ranged from 8.6 g/dL to 17.4 g/dL. Analysis of data from all subjects showed a bias ± standard deviation of −0.1 ± 1.1 g/dL for Pronto-7 SpHb and −0.1 ± 1.6 g/dL for HemoCue, compared with the hematology analyzer. SpHb could be used to safety screen between 73% and 95% of the population to rule out anemia, with SpHb values of ≥11.5g/dL to 13 g/dL and an additional 0.5% of the population to rule in anemia, with SpHb values of 7.5g/dL to ≤10 g/dL.

The authors concluded that their study shows noninvasive hemoglobin measurement with SpHb offers similar accuracy as another established point-of-care method, HemoCue, in an outpatient clinic environment. Its noninvasive and quick testing characteristics may translate into added benefits to patient care. The study was published on January 13, 2014, in the International Journal of Laboratory Hematology.

Related Links:

Long Beach Veterans Administration Healthcare System
Beckman Coulter
Masimo Corp.



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.